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Abstract
Background: Recent magnetic resonance spectroscopy (MRS) studies report that glutamine is
altered in the brains of schizophrenic patients. There were also conflicting findings on glutamate in
cerebrospinal fluid (CSF) of schizophrenic patients, and absent for glutamine. This study aims to
clarify the question of glutamine and glutamate in CSF of first episode and drug naive schizophrenic
patients.
Method:  Levels of glutamine and glutamate in CSF of 25 first episode and drug-naive male
schizophrenic patients and 17 age-matched male healthy controls were measured by a high
performance liquid chromatography.
Results: The ratio (126.1 (median), 117.7 ± 27.4 (mean ± S.D.)) of glutamine to glutamate in the
CSF of patients was significantly (z = -3.29, p = 0.001) higher than that (81.01 (median), 89.1 ± 22.5
(mean ± S.D.)) of normal controls although each level of glutamine and glutamate in patients was
not different from that of normal controls.
Conclusion: Our data suggests that a disfunction in glutamate-glutamine cycle in the brain may
play a role in the pathophysiology of schizophrenia.
Background
Multiple lines of evidence suggest that a dysfunction in
glutamatergic neurotransmission might be involved in
the pathophysiology of schizophrenia [1-6]. The amino
acid glutamate plays a central role in nitrogen metabolism
and participates in multiple biochemical pathways.
Released glutamate is taken up by glia, where it is con-
verted to glutamine, transported back to the presynaptic
neuron, and reconverted to glutamate [6,7]. Thus, it seems
that glutamate-glutamine cycle plays a role in the neuron-
glia communication in the synapse, and that impairment
of glutamate-glutamine cycle may be implicated in the
pathophysiology of schizophrenia [1-6].
By means of in vivo proton magnetic resonance spectros-
copy (MRS), a significant increase in glutamine level was
detected in the medial prefrontal cortex of never-treated
schizophrenic patients compared with controls [8]. In
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addition, a recent 4.0 T MRS study demonstrated that lev-
els of glutamine in the left anterior cingulate cortex and
thalamus of the never-treated patients with schizophrenia
were significantly higher than those of healthy controls
[9]. In contrast, significant lower levels of glutamine were
found in the left anterior cingulate cortex of medicated
patients with chronic schizophrenia than in the healthy
controls, suggesting the role of chronic medication [10].
Thus, it is possible that the glutamate-glutamine cycle
between neuron and glia may play a role in the glutamate
hypothesis of schizophrenia.
Although Kim et al. [11] first reported reduction of cere-
brospinal fluid (CSF) levels of glutamate in patients with
schizophrenia, the findings of subsequent studies are
inconsistent, with several report of no alteration in CSF
levels of glutamate [12-14]. Furthermore, it was reported
that a gradient for glutamate and glutamine in CSF was
lack, and that there were significant correlations between
the CSF and serum levels of glutamate (r = 0.67, p < 0.05)
and glutamine (r = 0.84, p < 0.01)[15]. Moreover,
sodium-dependent neutral amino acids transporters,
located in the abluminal membranes of the blood brain
barrier, are capable of actively removing neutral amino
acids from the brain [16]. These findings suggest that con-
centration of neutral amino acids in the extracellular fluid
of brain are maintained at ~10% of those of the blood
[15,16].
In this study, we investigated whether levels of glutamate
and glutamine or ratio of glutamine to glutamate in CSF
of first episode and drug naive schizophrenic patients are
different from those of age-matched healthy normal
controls.
Methods
Twenty-five male patients with schizophrenia (mean age
26.1 years, range 18–39) and 17 age-matched male
healthy subjects (mean age 27.3 years, range 22–44) with
no psychiatric disease were enrolled in Uppsala University
and Linkoping University Hospital, Sweden. All patients
diagnosed according to the DSM-III-R were first episode
and drug naive, i.e. they had never been treated with
antipsychotic drugs. In the morning (8:00–9:00) from
May 1997 to January 1998, CSF of subjects was obtained
by lumbar puncture (L4-L5), and twelve to eighteen µL of
CSF was collected with a 0.9 mm needle and the samples
were immediately frozen at -80°C, as reported previously
[17]. The ethics committee of each institute approved the
present study, and we received the informed consent from
the participants of the study.
Measurement of glutamate and glutamine levels were car-
ried out according to established methods [18] with a
slight modification using a high performance liquid chro-
matography (HPLC) system with fluorescence detection
(Shimadzu Corporation, Kyoto, Japan). Ten µL of the
human CSF was added with 10 µL of 0.1 M borate buffer
(pH 8.0) and 30 µL of 50 mM 4-fluoro-7-nitro-2,1,3-ben-
zoxadiazole (NBD-F; Tokyo Kasei Kogyo Co., Ltd., Tokyo,
Japan) in CH3CN. The reaction mixture was then heated
at 60°C for 2 min, and immediately supplemented with
100 µL of H2O/CH3CN (90/10) containing 0.1 % trifluor-
oacetic acid (TFA) to stop the reaction. Ten µL of the
resultant solution was injected into the HPLC system. A
reversed-phase ODS column (TSKgel ODS-80Ts, Tosoh
Corporation, Tokyo, Japan) was used for the separation
and quantification of glutamate and glutamine, and the
gradient elution of the mobile phase was kept at a con-
stant flow rate of 0.8 mL/min. Mobile phase 1a consisted
of H2O/CH3CN (90/10) containing 0.1 % TFA, and
phases 1b and 1c, of H2O/CH3CN (10/90) containing 0.1
% TFA and CH3CN, respectively. The time program for
gradient elution was programmed as follows: 0–50.5 min
1a: 1b : 1c = 95 : 5 : 0, 50.5–55.5 min 1a : 1b : 1c = 0 : 100
: 0, and 55.5–57 min, 1a : 1b : 1c = 0 : 0 : 100. The column
temperature of all columns was maintained at 35°C. Flu-
orescence detection was made at 530 nm with an excita-
tion wavelength at 470 nm.
Differences between two groups were analyzed using the
Mann-Whitney U-test. The relationship between two vari-
ables was examined using Spearman correlation coeffi-
cients. A p < 0.05 was considered significant.
Results
The CSF levels (421.7 µM (median), 468.1 ± 146.1 µM
(mean ± S.D.), 254.0–775.1 (range)) of glutamine in the
patients were not different (z = -1.038, p = 0.299) from
those (410.5 µM (median), 405.6 ± 108.6 µM (mean ±
S.D.), 219.8–689.0 (range)) of normal controls. The CSF
levels (4.17 µM (median), 4.25 ± 1.77 µM (mean ± S.D.),
2.22–8.88 (range)) of glutamate in the patients were not
different (z = -1.307, p = 0.191) from those (5.26 µM
(median), 4.73 ± 1.29 µM (mean ± S.D.), 2.54–6.51
(range)) of normal controls. However, the ratio (126.1
(median), 117.7 ± 27.4 (mean ± S.D.), 42.0–161.6
(range)) of glutamine to glutamate in the CSF of patients
was significantly (z = -3.29, p = 0.001) higher than that
(81.01 (median), 89.1 ± 22.5 (mean ± S.D.), 59.7–134.0
(range)) of controls (Table 1). Furthermore, we found sig-
nificant correlations between glutamate and glutamine in
normal controls (r = 0.549, p = 0.022) or patients (r =
0.780, p < 0.001).
Discussion
In this study, we found that the ratio of glutamine to
glutamate in the CSF of first episode and drug naive schiz-
ophrenic patients was significantly higher than that of
normal controls although each level of glutamine andBMC Psychiatry 2005, 5:6 http://www.biomedcentral.com/1471-244X/5/6
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Levels of glutamine and glutamate, and ratio of glutamine to glutamate in CSF of normal controls, and first episode and drug  naive schizophrenic patients Figure 1
Levels of glutamine and glutamate, and ratio of glutamine to glutamate in CSF of normal controls, and first episode and drug 
naive schizophrenic patients. (A) CSF levels of glutamine in patients were not different from those of normal controls. (B) CSF 
levels of glutamate in patients were not different from those of normal controls. (C) Ratios of glutamine to glutamate in 
patients were significantly higher than those of normal controls.BMC Psychiatry 2005, 5:6 http://www.biomedcentral.com/1471-244X/5/6
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glutamate in the CSF of patients was not significantly dif-
ferent from that of normal controls. To our knowledge,
this is a first report demonstrating that the ratios of
glutamine to glutamate in the first episode and drug naive
patients are significantly higher than those of normal con-
trols. In contrast, it was supposed earlier that alterations in
CSF levels of glutamate are not so prominent compared
with those in the brain [14]. Therefore, it is likely that a
difference in glutamate (or glutamine) levels between our
CSF study and MRS studies may be due to the difference
between CSF samples and specific corticolimbic regions.
However, it should be noted that alterations in the ratio of
glutamine to glutamate are detected in the CSF samples of
first episode and drug naive schizophrenic patients, sug-
gesting an abnormality of the glia-neuronal glutamate-
glutamine cycle in the brain of patients with
schizophrenia.
In general, glutamine is synthesized in astrocytes from
glutamate by the enzyme glutamine synthetase, found
exclusively in brain glia cells. Glutamine then crosses the
astrocytes to be transported into nerve cell terminals,
where it is converted again into the neurotransmitter
glutamate by glutaminase. It is reported that activities of
glutaminase and glutamic acid decarboxylase (GAD; the
rate-limiting enzyme in the synthesis of GABA by decar-
boxylation of glutamate) are significantly greater in the
dorsolateral prefrontal cortex (DLPFC) of schizophrenia
than in the control group, whereas activities of glutamate
dehydrogenase, glutamine synthetase, and GABA
transaminase in the DLPFC of schizophrenia are not dif-
ferent from the control group [19]. These findings suggest
that metabolism of glutamate and GABA might be altered
in the DLPFC of schizophrenic patients. Furthermore, it
has been reported that activity of glutamine synthetase
and glutamate dehydrogenase, the key enzymes involved
in glutamate-glutamine cycle between neuron and glia,
were markedly altered in the prefrontal cortex of schizo-
phrenic patients, suggesting abnormalities in the function
of glutamate-glutamine cycle in schizophrenic brain [20].
It is also well known that the glutamate-glutamine cycle
between neuron and glia is tightly related to glutamate
neurotransmission, glutamatergic function, and their reg-
ulation in human brain [7]. Taken together, it is likely that
a dysfunction in glutamate-glutamine cycle in the brain
may play a role in the pathophysiology of schizophrenia,
supporting the glutamate hypothesis of schizophrenia.
As described in introduction, sodium-dependent amino
acids transporters, located in the abluminal membranes
of the blood brain barrier, are capable of actively remov-
ing amino acids from the brain [16,20,21]. Sodium-
dependent amino acids transporter are capable of pump-
ing both glutamine (system N) and glutamate (glutamate
transporters EAAT-1, 2, and -3) from the extracellular fluid
into endothelial cells [20,21]. The luminal facilitative car-
riers for both glutamate and glutamine can then transport
them to the blood [16,20,21]. Therefore, the concentra-
tions of naturally occurring amino acids in the CSF [pre-
sumably similar to the extracellular fluid of brain] are
~10% of those of the blood [15,16]. Taken together, it
seems that alteration in the transport mechanisms regulat-
ing levels of glutamate and glutamine in CSF may be
implicated in elevated glutamine/glutamate ratio in CSF
of schizophrenic patients although further study is
necessary.
Conclusion
Our findings suggest that a dysfunction in glutamate-
glutamine cycle between neuron and glia may play a role
in the pathophysiology of schizophrenia, supporting the
glutamate hypothesis of schizophrenia.
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